{"id":"NCT03243305","sponsor":"Evofem Inc.","briefTitle":"AMP002 Phase III Contraceptive Study","officialTitle":"AMPOWER A Single-arm, Phase III, Open Label, Multi-center, Study in Women Aged 18-35 Years of the Contraceptive Efficacy and Safety of Phexxi™ (Previously Referred to as AMPHORA®) Contraceptive Vaginal Gel","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-07-24","primaryCompletion":"2018-11-29","completion":"2018-11-29","firstPosted":"2017-08-09","resultsPosted":"2020-07-22","lastUpdate":"2020-09-17"},"enrollment":1384,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Contraception"],"interventions":[{"type":"DRUG","name":"AMPHORA","otherNames":[]}],"arms":[{"label":"Interventional","type":"EXPERIMENTAL"}],"summary":"This is a single-arm, open-label, Phase III study in approximately 100 sites in the United States (US) over seven cycles of use in women aged 18 to 35 years who are at risk of pregnancy.","primaryOutcome":{"measure":"Number of Subjects With Pregnancy Outcomes to Measure Contraceptive Efficacy","timeFrame":"10 months","effectByArm":[{"arm":"Interventional","deltaMin":100,"sd":null}],"pValues":[{"comp":"OG000","p":null}]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":null},"locations":{"siteCount":87,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":17,"n":1330},"commonTop":["Vulvovaginal burning sensation","Vulvovaginal pruritus","Urinary tract infection","Vulvovaginal pain","Vulvovaginal mycotic infection"]}}